MedTrace Logo

Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy

NCT05295407 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2026-02-27

No results posted yet for this study

Summary

Condition: Prostate cancer Intervention: Biopsy and inherited risk assessment

Conditions

Interventions

GENETIC

Genetic Assessment

The trial is to observe whether inherited risk, including rare pathogenic mutations (RPMs) in several major genes and SNPs-based genetic risk scores (GRS), is correlated with prostate cancer detection rate from diagnostic prostate biopsy.

Sponsors & Collaborators

Principal Investigators

  • Jianfeng Xu, MD, Dr.PH · Endeavor Health

Eligibility

Min Age
40 Years
Max Age
69 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-13
Primary Completion
2026-12-13
Completion
2027-12-13

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05295407 on ClinicalTrials.gov